Ratings Hainan Poly Pharm. Co., Ltd

Equities

300630

CNE100002N10

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
12.35 ^CNY	-18.75%		-.--%	-45.40%

May. 14	China Grants Registration Approval for Antibacterial Drug	MT
May. 06	Hainan Poly Pharm Gets GMP Certificate From Saudi Authorities	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
With a P/E ratio at 11.6 for the current year and 9.96 for next year, earnings multiples are highly attractive compared with competitors.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Over the past twelve months, analysts' opinions have been revised negatively.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HAINAN POLY PHARM. CO., LTD	-45.40%	765M	C-
ELI LILLY AND COMPANY	+37.40%	727B	C+
JOHNSON & JOHNSON	-7.97%	354B	C+
MERCK & CO., INC.	+15.46%	328B	B-
ABBVIE INC.	-0.53%	277B	C+
ASTRAZENECA PLC	+13.47%	243B	B+
NOVARTIS AG	+7.35%	205B	B-
ROCHE HOLDING AG	-6.42%	203B	A+
AMGEN INC.	+3.63%	164B	C+
PFIZER, INC.	-2.08%	164B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders